Combined therapy in anxiety disorders: Current data and recommendations for the clinical practice;Kombinationstherapie bei angststörungen: Aktuelle datenlage und empfehlungen für den klinischen alltag

Verhaltenstherapie

Volumn 11, Issue 3, 2001, Pages 160-172

  Rufer, Michael ^a   Hand, I ^a   Peter, H ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Anxiety disorders; Behavior therapy; Combined therapy; Outcome evaluation; Psychopharmacotherapy

Indexed keywords

FLUVOXAMINE; IMIPRAMINE; MOCLOBEMIDE; PAROXETINE;

AGORAPHOBIA; ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL PRACTICE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; PANIC; PSYCHOPHARMACOLOGY; RELAPSE; REVIEW; SYMPTOMATOLOGY;

EID: 18144432204     PISSN: 10166262     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Zum stellenwert therapeutisch-pharmakologischer kombinationstherapien bei angststörungen
2. The patient with comorbid depression and anxiety: The unmet need
3. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine study group
4. Current treatments of the anxiety disorders in adults
5. Panic and generalized anxiety disorders: Nature and treatment
6. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial
7. Therapierefraktäre panikstörung - Erfolg einer kombinationsbehandlung mit imipramin, moclobemid sowie verhaltenstherapie
8. Paroxetin in der therapie der agoraphobie und alkoholabhängigkeit
9. Pharmakotherapie der angststörungen
10. Pharmakotherapie der sozialen phobie
11. Aktuelle standards der pharmakotherapie von angststörungen
12. Treatment of nonphobic anxiety disorders: A comparison of nondirective, cognitive, and coping desensitization therapy
13. Comorbidity among anxiety disorders: Implications for treatment and DSM-IV
14. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders
15. Diagnostic comorbidity in panic disorder: Effect on treatment outcome and course of comorbid diagnosis following treatment
16. Predictors of alprazolam discontinuation with and without cognitive therapy in panic disorder
17. Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: A long-term follow-up of the peoria and dartmouth studies
18. Anxiety management for persistant anxiety
19. Comparison of behavior therapy in the treatment of generalized anxiety disorders
20. The asesssment and treatment of performance anxiety in musicians
21. A comparison of cognitive therapy, applied relaxation and imipramine in treatment of panic disorder
22. A meta-analysis of treatments for panic disorder
23. Two-year follow-up of agoraphobics after exposure and imipramine
24. Dyspnea and panic attacks
25. Cognitive behavior therapy versus supportive therapy in social phobia: A randomized controlled trial
26. Treatment of social phobia with clonazepam and placebo
27. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
28. Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone
29. Systematischer überblick und leitfaden für die auswahl selektiver serotonin-wiederaufnahmehemmer
30. Prescribing patterns in agoraphobia with panic attacks
31. Long-term follow-up of agoraphobics treated by brief intensive group cognitive behavioural therapy
32. The treatment of social phobia
33. Overcoming resistance to exposure in panic disorder with agoraphobia
34. Mißerfolge in der verhaltenstherapie
35. Discontinuation of alprazolam treatment in panic patients
36. Wirksamkeit von venlafaxinkapseln mit verzögerter wirkstofffreisetzung bei nichtdepressiven, ambulanten patienten mit general-isierter angststörung
37. Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study
38. A meta-analysis of treatment outcome for panic disorder
39. Verhaltenstherapie und kognitive therapie in der psychiatrie
40. Verhaltenstherapie als kurzzeit-psychotherapie
41. Verhaltenstherapie bei schweren phobien und panik - Psychologische und medizinische aspekte
42. Expositions-Reaktions-Management (ERM) in der strategisch-systemischen verhaltenstherapie
43. Group exposure in vivo for agoraphobics (1974): A multifaceted pilot study and ist impact on subsequent agoraphobia research
44. Verhaltenstherapie bei patienten mit angsterkrankungen
45. Exposure in vivo of agoraphobics: Contributions of diazepam, group exposure, and anxiety evocation
46. Combined cognitive behavioral and time-limited alprazolam treatment of panic disorder
47. Cognitive behvioral group treatment for social phobia: Effectiveness at 5-year follow-up
48. Cognitive behavioral group therapy vs phenelzine therapy for social phobia
49. Where are we going with SSRIs?
50. Long-term follow-up after a drug trial for panic disorder
51. The relationship between anxiety disorders and alcohol use disorders: A review of major perspectives and findings
52. Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified?
53. Agoraphobics 5 years after imipramine and exposure
54. Anxiety disorders and obsessive compulsive disorder
55. Empfehlungen zur diagnostik und therapie der sozialen phobie
56. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia
57. Imipramine in brief therapist aided exposure in agoraphobics having self-exposure homework
58. Alprazolam and exposure alone and combined in panic disorder with Agoraphobia
59. Cognitive-behavioral group therapy for panic disorder in the general clinical setting: A naturalistic study with 1-year follow-up
60. Treatment of panic and agoraphobia. An integrative review
61. Agoraphobia: Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine
62. Two year follow-up of exposure and imipramine treatments of agoraphobia
63. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia
64. Behavioral, cognitive and pharmacological treatments of panic disorder with agoraphobia: Critique and synthesis
65. Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group
66. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants
67. Outcome of panic disorder. Relationship to diagnostic subtypes and comorbidity
68. Moclobemide in the treatment of social phobia
69. The influence of depression outcome of cardiac phobia (panic disorder)
70. Paroxetine in the treatment of panis disorder. A randomised, double-blind, placebo-controlled study
71. Does concurrent drug intake affect the long-term outcome of group cognitive behaviour therapy in panic disorder with or without agoraphobia?
72. Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder
73. Medication and psychological treatment for panic disorder: A case of competition or synergy?
74. Kombinationsbehandlung von agoraphobien und panikstörungen mit verhaltens- und psychopharmakotherapie. Kritische beurteilung von meta-analysen
75. Additive effekte kombinierter psycho- und pharmakotherapie für depressive patienten: Illusion oder tatsache?
76. Cognitive behavior therapy for treatment-refractory panic disorder
77. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care
78. Maintenance drug treatment for panic disorder II: Short- and long-term outcome after drug taper
79. Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder
80. Paroxetine efficacy in the treatment of generalized anxiety disorder
81. Effektivität psychologischer therapien von panik und agoraphobie: Meta-analysen auf störungsebene
82. Effektivität psychologischer therapien von spezifischer phobie und zwangsstörung: Meta-analysen auf störungsebene
83. Effektivität psychologischer therapien von generalisierter angststörung und sozialer phobie: Meta-analysen auf störungsebene
84. A review of the epidemiology and approches to the treatment of social anxiety disorder
85. Placebo-controlled trial of moclobemide in social phobia
86. Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies
87. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?
88. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder - Conclusions from combined treatment trials
89. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
90. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa
91. The treatment of social phobia: A critical assessment
92. Combined pharmacological and behavioral treatment for agoraphobia
93. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants
94. A meta-analysis af the treatment of panic disorder with or without agoraphobia: A comparison of psychopharmacological, cognitive-behavioral, and combination treatment
95. Psychopharmacological treatment of social phobia: A double-blind, placebo-controlled study with fluvoxamin
96. Clinical effects of buspirone in social phobia. A double-blind placebo-controlled study
97. The long-term treatment of social phobia with moclobemide
98. Effekts of concurrent diazepam treatment on the outcome of exposure therapy of agoraphobia
99. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders
100. Acute and delayed effects of alprazolam on flight phobics during exposure
101. Der langzeitverlauf unbehandelter angststörungen: Wie häufig sind spontanremissionen?
102. Komorbiditätsstrukturen bei angststörungen - Häufigkeit und mögliche implikationen
103. Exposure in vivo vs. social scills training for social phobia: Long-term outcome and differerntial effects
104. Pharmakotherapie generalisierter angststörungen mit fluspirilen
105. Treatment of agoraphobia with group exposure in vivo and imipramine
106. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo